Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326913 | 1.00 | MCHR1 (0.55) | MCHR1CHRM1HTR2ACYP2D6ADK | |
| SCHEMBL5225144 | 0.92 | MCHR1 (0.49) | MCHR1CHRM1HTR2ACYP2D6ADK | |
| SCHEMBL2321344 | 0.91 | MCHR1 (0.52) | MCHR1CHRM1HTR2ACYP2D6ADK | |
| SCHEMBL6373063 | 0.90 | MCHR1 (0.46) | MCHR1CHRM1HTR2ACYP2D6ADK | |
| SCHEMBL5224293 | 0.90 | MCHR1 (0.46) | MCHR1CHRM1HTR2ACYP2D6ADK | |
| SCHEMBL5225175 | 0.89 | MCHR1 (0.59) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL5230363 | 0.88 | MCHR1 (0.44) | MCHR1CHRM1HTR2ACYP2D6ADK | |
| SCHEMBL6371812 | 0.88 | MCHR1 (0.44) | MCHR1CHRM1HTR2ACYP2D6ADK | |
| SCHEMBL6367242 | 0.87 | MCHR1 (0.58) | MCHR1CHRM1HTR2ACYP2D6ADK | |
| SCHEMBL6367236 | 0.87 | MCHR1 (0.58) | MCHR1CHRM1HTR2ACYP2D6ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737824-A2 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
| WO-2005103032-A2 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MCHR1 1/4885CHRM1 49/4885HTR2A 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.